Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2769)	7/13/2011 2:27:05 PM
From: Jibacoa	Respond to of 3722

PPHM was up 14% at its intraday H and is still up 10.55% on volume of > 563Ks, which is still below 2x its ADV. bigcharts.marketwatch.com PPHM is due to report results of its 4thQ and fiscal year tomorrow. <g> It recently reported some data of its PII of bavituximab on patients with NSCLC that showed an objective response rate (ORR) of 43% and a median progression-free survival (PFS) of 6.1 months, vs. historic control data of 15% ORR and 4.5 months PFs. They think that data looks encouraging, and are also conducting another PII, in which bavituximab is being studied in combination with docetaxel, also in patients with NSCLC, as well as in combination with pemetrexed and carboplatin in a PIb for the same application. The ACTAY is $7.50 The short ratio is around 9.20 and with some good news, there could be a short squeeze.<g> The price has drifted down some since the intraday H at 11:00am, but is still holding above the EMA20 on the 10 minutes chart.<g> Bernard